Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.
|Articles|November 1, 2006
Part D puts PBMs in the political spotlight
The emergence of pharmacy benefit management companies (PBMs) as major players in drug benefit design and pricing has generated criticism as well as praise. PBMs previously served as drug benefit administrators for employers and other payers. But as sponsors of Medicare Prescription Drug Plans (PDPs), they now assume risk and design coverage and payment options.
Advertisement
Advertisement
Related to this article
The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.
In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.
The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
McKesson, private equity firm buy home infusion company, Option Care Health
2
Medicare Advantage needs fixing. Here are 3 feasible repairs
3
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
4
Blood RNA panel linked to lung cancer risk up to 10 years before diagnosis
5